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Exosomes: a potential key target in cardio-renal syndrome
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Exosomes have proven roles in regulating immune response, antigen presentation, RNA
and protein transfer, and cell–cell (organ–organ) interaction/signaling. These microvesicles
can be considered a mechanism of non-classical secretion of proteins, and they represent
a subproteome, thus assisting in the difficult task of biomarker discovery in a biological fluid
as urine, plasma, or serum. A potential role of exosomes in the cardio-renal syndrome is
currently underexplored. Cardiovascular disease continues to be the leading cause of mor-
bidity and mortality worldwide and, particularly, rates of cardiovascular events and death
consistently increase as kidney function worsens. In other words, chronic kidney disease
acts as a risk multiplier. Unfortunately, the relationship between markers of cardiovascular
risk in kidney pathology often differs from that in the general population. Efforts in the
search for novel action mechanisms simultaneously operating in both pathologies are thus
of maximum interest. This article focuses to the role of exosomes in cardiovascular and
renal diseases, in the search for novel key targets of interaction between heart and kidneys.
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THE CARDIO-RENAL SYNDROME
The term “cardio-renal syndrome” (CRS) encloses a scenario of
clinical interactions in which cardiac and renal dysfunction coex-
ists (1). The cross-talk between the heart and the kidneys is clearly
evidenced but not fully understood. Observational and clinical
data showed that acute/chronic worsening of kidney function
directly contributes to acute/chronic cardiac disease and vice versa,
constituting the CRS.
Chronic kidney disease (CKD) is increasingly recognized as a
major public health problem and its prevalence is continuously
rising. Defined as an irreversible progressive loss of renal func-
tion for 3 months or longer, it is categorized into five stages of
increasing severity (CKD1-5). In early stages, it develops silently
and asymptomatic, which enormously difficult early diagnosis and
intervention. In CKD patients, rates of cardiovascular events and
death consistently increase as kidney function becomes worse.
Thus, CKD acts as a risk multiplier. The risk of unfavorable car-
diovascular prognosis increases as renal insufficiency progresses
toward end stage renal disease (ESRD), reaches its maximum,
and persists following successful renal transplantation. Subjects
with mild to moderate renal dysfunction have a higher proba-
bility of dying by a cardiovascular event than due to the kidney
disease itself before reaching ESRD. In fact, the American Heart
Association (AHA) stated that CKD patients should be regarded
as the highest risk group for subsequent cardiovascular disease
(CVD) (2).
It may be thought that risk factors and misregulated mole-
cules known to be acting in CVD in the general population can be
directly translated into the renal disease frame. However, the rela-
tionship between risk markers and CV events in kidney pathology
often differs from that in the general population. One of the main
reasons is that traditional CV risk factors, e.g., age, male gender,
hypertension, diabetes, dyslipidemia, smoking, overweight, and
hyperhomocysteinemia are highly prevalent in CKD. Additionally,
contribution of risk factors specifically associated to kidney disease
should be added, e.g., anemia, calcium-phosphate disorders, elec-
trolyte imbalances, chronic inflammation, oxidative stress, hyper-
catabolism, uremic condition, and vitamin D deficiency (3). Some
clinical trials focus on known drugs acting to control abovemen-
tioned risk factors (blood pressure management, lipid lowering,
antiplatelet therapy, etc.). Unfortunately, the results are usually
unexpected or not convincing, finding a non-clear response in the
adequate direction. Additionally, most of the studies about CVD
in CKD are carried out from a post hoc subgroup analysis of larger
trials, which were not specifically designed to investigate effects on
CKD population, so that final conclusions should be postponed
until further evidence is found (4). In other cases, cardiovascular
trials even excluded CKD patients from enrollment. Thus, despite
of research efforts, active cardioprotective treatment is underem-
ployed in renal disease patients, probably due to the uncompleted
knowledge of the cardio-renal puzzle.
In this context, documented evidence exists to consistently
prove that cardiovascular complications should be considered a
key, unsolved and state-of-the art issue in kidney disease, in terms
of early on-time diagnosis, accurate prognosis prediction, and
in-depth understanding of underlying mechanisms.
EXOSOMES REFLECT PATHOPHYSIOLOGICAL CHANGES IN
THE KIDNEY
The classical pathway of exosome formation involves intraluminal
vesicles (ILVs) formation within multivesicular bodies (MVBs)
whose membrane fuses with the plasma membrane and release
the ILVs, called exosomes once secreted (5). A potential role in the
pathophysiology of the kidney has been attributed to exosomes,
which may participate as mediators of intercellular communica-
tion, activate signaling mechanisms in the target cell, transfer their
content in mRNAs, miRNAs and proteins, or just constituting a
way of cellular contents disposal (6, 7) (Table 1).
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Table 1 | Overview of the main roles described for exosomes in cardiovascular and renal diseases.
Sample Disease Main findings Reference
BIOMARKERS SOURCE
Urine Aldosteronism pNCC, marker of aldosteronism (23)
Urine AKI and podocyte injury Transcription factors in urinary exosomes (11)
ATF3, marker of early AKI
WT-1, marker of early podocyte injury
Urine Diabetic nephropathy WT-1, marker of DN (20)
Urine Diabetic nephropathy VDAC1, AMBP, MLL3 markers of DN (18)
Urine Renal I/R injury Aquaporin-1, novel exosomal marker in renal I/R injury (22)
Urine DGF in renal transplantation Exosomal NGAL correlates with DGF patients (17)
INTERCELLULAR COMMUNICATION
Kidney cortical collecting duct cells Functional Aquaporin-2 transfer between kidney cells by exosomes (13)
Urinary exosome-like vesicles PKD proteins, shed in urinary membrane particles, which interact with primary cilia (6)
Model of kidney injury Exosomes produced by injured epithelial cells activate fibroblasts by delivering TGF-b1 mRNA (7)
Cardiomyocytes HIF-1α initiates expression of TNF-α mediated by exosomes in hypoxia (38)
Vascular smooth muscle cells VSMC-derived exosomes mediate vascular calcification (39)
Endothelial cells HSP70 secretion from endothelial cells is exosome-dependent (40)
CARDIOPROTECTION
MSCs After ischemic preconditioning, MSCs secrete exosomes enriched with miR-22 (31)
Rats heart Remote cardioprotection after ischemic preconditioning is mediated by heart extracellular vesicles (41)
CPCs from mouse hearts CPC-exosomes, as a therapeutic vehicle for cardioprotection (34)
AKI: acute kidney injury; DN: diabetic nephropathy; DGF: delayed graft function; PKD: polycystic kidney disease; MSCs: mesenchymal stem cells; CPC: cardiac
progenitor cells.
Representative examples.
In the kidney, exosomes can be released by cells as podocytes,
pass through the renal tubule and they can either be uptaken by
recipient epithelial cells of the collecting duct, or influence them
through secretion of their content. Exosomes finally appear in
urine (8, 9). Thus, these vesicles are direct messengers of what
is happening in the kidney, both in acute and chronic damage,
carrying molecular markers of renal dysfunction and structural
injury (10, 11). More than a way of exocytic cell waste elimina-
tion, they should be considered as key molecular targets and a
valuable source of potential biomarkers, particularly when kidney
tissue is not available or as a non-invasive alternative to biopsy-
based diagnosis (12). Aquaporin-2 present in exosomes released
from collecting duct cells was shown to be physiological regu-
lated and a close reflection of cellular expression, pointing to a
novel mechanism of cell-to-cell communication inside the kidney
(13). Another example of their role in intercellular communica-
tion is the observation that renal brush border-derived exosomes
can induce crystallization in nephrolithiasis (14). In the same
line, a still underexplored role in transplantation or protection
against acute kidney injury (AKI) or toxics negative effect has
been attributed to microvesicles in general and exosomes in par-
ticular (15, 16). A recent study shows a high presence of NGAL
protein in urinary exosomes. This protein has been described as
a good marker of AKI, and the reported correlation of urinary
exosomal NGAL levels with delayed graft function after kidney
transplantation point to the exosomal fraction as a more sensi-
tive substrate to evaluate early biomarkers of prognosis in this
context (17).
Zubiri et al. have recently published a panel of altered proteins
composed by MLL3, AMBP, and VDAC1 in the urinary exosomes
of patients with diabetic nephropathy (DN) compared to healthy
controls (18). DN is the main cause of ESRD,but underlying mech-
anisms are not fully understood and renal damage observed in
biopsied tissue does not always correlate with measurable indi-
cators as microalbuminuria. In the search for novel and earlier
indicators, urinary exosomes have been investigated in an ani-
mal model of DN finding Xaa-Pro dipeptidase and Major Urinary
Protein 1 increased or decreased, respectively (19). Quantitation of
damaged podocyte in urine has been proposed as an indicator of
renal damage; however, it is not feasible for early detection of DN.
Podocyte injury can be evaluated by means of Wilm’s Tumor-1
protein levels, and although it could not be detected in urine from
focal segmental glomerulosclerosis (FSGS) patients, Kalani et al.
recently showed its predominant presence in urinary exosomes of
diabetic patients and increased levels when renal function wors-
ens (20). Markers of renal damage in the context of AKI have also
been investigated in urinary exosomes pointing to Fetuin-A and
Aquaporin-1 proteins (21, 22). The phosphorylated (active) form
of the sodium chloride cotransporter (pNCC) was investigated
in aldosteronism and discovered as an indicator of the biological
activity of aldosterone and, potentially, as clinical biomarker for
primary aldosteronism (23).
Thus, interest of exosomal research in kidney pathology is
twofold: as a rich source of novel markers, which promisingly
reflect what is happening in progressively or acute damaged kid-
ney tissue, and as molecular messengers between the different parts
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of the nephron contributing to its optimum functionality by the
uptake and release of their content.
EXOSOMES AND CARDIOVASCULAR DISEASE
Atherosclerosis develops silently and progressively. It is a multifac-
torial disease that starts with endothelium dysfunction, followed
by accumulation of inflammatory cells (macrophages, lympho-
cytes), lipoproteins, lipids, and fibrous tissue in the wall of large
arteries, leading to intima hyperplasia and proliferation of vascu-
lar smooth muscle cells (VSMC) within the intima. In advanced
lesions, necrosis of macrophages derived foam cells and VSMC
results in a lipid-rich core covered by a fibrous cap, which pro-
tects the lesions from rupture and consists mainly of collagen
and extracellular matrix (ECM) proteins. Plaque rupture and the
ensuing thrombosis commonly cause the most acute complica-
tions of atherosclerosis such as unstable angina or myocardial
infarction (MI) (acute coronary syndrome) or stroke (24). The
main problem is that we are facing an asymptomatic develop-
ment of the pathology in which different cellular types are acting
simultaneously.
Only recently, a potential implication of exosomes in CVDs has
been raised (25) (Table 1). Similar to what has been described in
pancreatic β-cells, exosomes could interact with the ECM via exo-
somal integrins (26) pointing to a role in plaque unstability or, in
the opposite way, in fibrous cap protection. Several studies show
an increased amount of microvesicles released in CVD and, in
particular, platelets are known to release exosomes, which may be
involved in the complex cross-talk among different cell types dur-
ing atherosclerosis development (27). The capacity of exosomes
released by cardiomyocytes to transfer DNA and RNA to different
cells has been shown (28). However, the exosomes involvement
either in vascular diseases or in cardioprotection mechanisms has
not been deeply investigated and fully unraveled. In this sense,
preceded by studies showing that cardiac and circulating miRNAs
are altered following MI, intercellular communication between
heart and bone marrow through released exosomal miRNAs has
been hypothesized as a protective/regeneration mechanism after
ischemia (29–31). Apparently, similar mechanisms to those oper-
ating in preconditioning take place in cardioprotection conferred
by exosomes (32–34).
Additionally, exosomal surface can be functionalized to direct
them toward a specific target. In this way, they can be converted
into therapeutic transporters as they may be acting on a solely
cellular type (i.e., cardiac cells). The drug efficiency could be so
increased and side effects could be minimized. In a similar way,
exosomes have been proposed as ideal therapeutic agents in regen-
erative medicine, particularly in stem cell based therapies to treat
acute MI (35).
PERSPECTIVES: EXOSOMES, A NOVEL TARGET IN THE
CARDIO-RENAL PUZZLE
Deeping insight the cardio-renal puzzle demands for expanded
knowledge of many still missing pieces. This challenging mul-
tidisciplinary task should be accomplished in two main direc-
tions: discovery of novel markers of disease and understanding
the underlying physiopathological mechanisms taking place. In
general, biomarkers can be classified attending to the kind of
information provided in (a) risk assessment, (b) screening mark-
ers to distinguish between healthy and pathologic condition, (c)
prognostic markers able to predict course of disease or therapy
effect, (d) stratification markers to envisage responders and non-
responders to drug, and (e) therapy monitoring, able to monitor
the efficacy of treatment once the responder status is established
(36). The difficulties behind novel biomarkers discovery make
sense particularly in relation to approach cardiac or renal tissue.
Totally different from other diseases as cancer pathology in
which biopsy procedures are routinely indicated, it is very much
difficult, when not unfeasible, directly approach the heart or the
kidney to investigate pathological changes of significance. In cer-
tain disorders as DN, a diagnosis based on clinical evidences
usually takes place late in the course of disease or when damage at
tissue level is already irreversible. Atherosclerosis silent and asymp-
tomatic development results in the worst case in a fatal event, and
there is lack of effective preventive markers to stratify risk and
design preventive measurements individually.
Biological fluids such as serum, plasma, or urine are being
explored in the different contexts in the search for diagnostic,
prognostic, or risk markers. One of the main difficulties is the
wide dynamic range of the sample when proteins are to be inves-
tigated. Fishing low-abundance molecules can be facilitated when
approaching a certain subproteome such as the cellular or tissue
secretome. In the same way, isolation of exosomal fraction from a
biological fluid or secretome allows narrowing the complexity of
the sample and focusing the search in a more specific target (37).
Exosomal isolation from the original source (cell/tissue secretome,
plasma, urine, platelets, etc.) is not a trivial task, and it should
be carefully approached. Indeed, particular limitations has been
pointed to in terms of “purity” of isolated exosomes, in the sense
that care should be taken whenever a specific role is to be attributed
specifically to these microvesicles instead of to microparticles or
apoptotic blebs or mixtures of both. In urine, exosomes represent
only a 3% of the whole proteome, thus they constitute an enriched
subproteome with reduced complexity compared to the whole
urine. In this way, low-abundance molecules that may have patho-
physiological significance are enriched against high-abundance
ones. Their value as source of potential markers of disease is exem-
plified when the exosomal content can directly reflect the tissue
situation.
Apart from a source of potential novel markers, they act as
a way of intercellular communication, which although proved
with sufficient evidence is currently underexplored. This exoso-
mal role has been shown, for instance, in terms of proteins and
miRNAs transfer from the origin cell and the target cell or acting
as functionalized messengers to ensure specific drug delivery to
the desired point of action. Related to cardioprotection following
an acute cardiovascular event (e.g., MI) or to ameliorate the con-
sequences of ischemia-reperfusion, there are evidences pointing
to an active role for exosomes in ischemic signaling, myocardial
repair, and communication between heart and bone marrow. This
exosomal role acquires special significance in the context of CRS
in which the cross-talk between heart and kidneys is known but
not gone through.
Once overcome methodological difficulties, exosomal research
in the context of cardio-renal pathology is therefore more than
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FIGURE 1 | Exosomes and the cardio-renal puzzle.
justified (Figure 1). Exosomes are currently being of increased
consideration and they constitute a promising field in this and
other pathologies.
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